The outcomes of this study have provided further insight into the pharmacological properties of the PTHrP (107–111) C-terminal peptide osteostatin, which alleviates the acute oxidative and inflammatory processes in both crystal-induced pseudogout and gouty arthritis models. This evidence concerns the gene PTHLH and gout.